Description: <b>Cannabichromene (CBC)</b> is a phytocannabinoid found in the Cannabis plant. It has anti-inflammatory, antitumor and anticonvulsant properties, and may affect THC psychoactivity.<br>
<p><b>Cannabichromene</b> (CBC) is a non-psychotropic phytocannabinoid produced by <i>Cannabis sativa</i> through decarboxylation of cannabichromenic acid (CBCA). It is formally classified as a plant-derived small-molecule cannabinoid and, in oncology, is best considered an exploratory adjunctive natural product rather than an established anticancer drug. Standard abbreviation: CBC. Current evidence supports a receptor-mixed pharmacology centered on CB2-preferring signaling, TRPA1 activity, and modulation of endocannabinoid tone, but the human evidence base remains sparse. In the Nestronics print page for pid 53, the product is present but no cancer/normal-cell pathway targets are currently indexed, so the mechanistic interpretation below relies primarily on external literature rather than site-specific target listings.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>CB2 receptor agonism with predominantly anti-inflammatory and immunomodulatory signaling</li>
<li>TRPA1 activation and subsequent desensitization, relevant to inflammatory and nociceptive modulation</li>
<li>Endocannabinoid tone modulation through inhibition of endocannabinoid cellular uptake and weak MAGL inhibition</li>
<li>Suppression of inflammatory nitric oxide output in activated macrophages</li>
<li>Context-dependent antiproliferative and pro-apoptotic effects in cannabinoid-containing extract systems, with CBC often acting as one component rather than a fully validated stand-alone anticancer effector</li>
<li>Clinical translation constraint from variable oral exposure, first-pass metabolism, formulation dependence, and limited human efficacy data</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> CBC is lipophilic and formulation-sensitive. Human oral PK data exist, but mainly from mixed cannabinoid oil products rather than purified CBC. Oral exposure is variable, first-pass metabolism is relevant, and current PK reviews identify low/variable bioavailability and limited clinical PK characterization as major translational constraints.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> This is an important limitation. Mechanistic and antiproliferative findings are mainly preclinical, and many in-vitro cannabinoid concentrations used in oncology-oriented studies are likely above readily achievable systemic exposure with currently described oral human CBC dosing. CBC is therefore more plausible at present as a pharmacology signal or adjunctive lead than as a validated concentration-achievable stand-alone anticancer agent.</p>
<p><b>Clinical evidence status:</b> Preclinical and early human PK only. No established CBC-specific randomized oncology efficacy trials were identified. Regulatory/clinical use is not established for purified CBC as an approved anticancer drug.</p>
<h3>Mechanistic interpretation</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>CB2 signaling</td>
<td>↓ inflammatory support signals (context-dependent)</td>
<td>↓ inflammatory activation</td>
<td>R-G</td>
<td>Immunomodulatory anti-inflammatory bias</td>
<td>Best-supported direct receptor mechanism. CBC behaves as a selective CB2 agonist with little meaningful CB1 activity in the cited receptor studies. Anticancer leverage is indirect and context-dependent rather than firmly cytotoxic.</td>
</tr>
<tr>
<td>2</td>
<td>TRPA1 activation desensitization</td>
<td>↔ direct tumor kill uncertain</td>
<td>↓ nociceptive and inflammatory signaling</td>
<td>P-R</td>
<td>Sensory-inflammatory modulation</td>
<td>TRPA1 appears mechanistically relevant for CBC pharmacology. In oncology this is more plausible for inflammation/pain biology than for a robust stand-alone tumoricidal mechanism.</td>
</tr>
<tr>
<td>3</td>
<td>Endocannabinoid tone AEA uptake MAGL</td>
<td>↔ mixed</td>
<td>↔ mixed</td>
<td>R-G</td>
<td>Indirect ECS amplification</td>
<td>CBC has been reported to inhibit endocannabinoid cellular reuptake and weakly inhibit MAGL, which could alter local endocannabinoid tone. Net cancer relevance is model-dependent and presently secondary.</td>
</tr>
<tr>
<td>4</td>
<td>Macrophage nitric oxide inflammatory axis</td>
<td>↓ pro-tumor inflammatory milieu (possible)</td>
<td>↓ NO output in activated macrophages</td>
<td>R-G</td>
<td>Anti-inflammatory effector suppression</td>
<td>Strong preclinical evidence shows CBC reduces nitrite / nitric oxide output in activated macrophages and improves murine colitis. This supports anti-inflammatory action but not a CBC-specific clinical anticancer effect.</td>
</tr>
<tr>
<td>5</td>
<td>Apoptosis and migration inhibition</td>
<td>↓ viability; ↓ migration/invasion (extract-dependent)</td>
<td>↔ unknown</td>
<td>G</td>
<td>Preclinical antiproliferative signal</td>
<td>Anticancer findings exist in bladder and other experimental systems, but CBC is often part of active extract fractions or cannabinoid combinations. Attribution to purified CBC alone remains lower-confidence than for its anti-inflammatory pharmacology.</td>
</tr>
<tr>
<td>6</td>
<td>Estrogen receptor antagonism</td>
<td>↓ ER signaling (weak, high concentration only)</td>
<td>↔ uncertain</td>
<td>R</td>
<td>Possible endocrine interaction</td>
<td>Recent breast-cancer-related in vitro work suggests CBC can show ER antagonism at 10 μM, but this is not yet a core validated mechanism and may be influenced by concurrent cell-viability effects.</td>
</tr>
<tr>
<td>7</td>
<td>ROS NRF2</td>
<td>↔ not established as core</td>
<td>↔ not established as core</td>
<td></td>
<td>Not a primary defining axis</td>
<td>ROS/NRF2 are not well established as central CBC mechanisms from current higher-confidence sources, so they should not be foregrounded for this product at present.</td>
</tr>
<tr>
<td>8</td>
<td>Clinical Translation Constraint</td>
<td>Exposure limitations</td>
<td>Exposure limitations</td>
<td>G</td>
<td>PK and evidence bottleneck</td>
<td>Human PK data show measurable oral exposure, but formulation dependence, first-pass metabolism, sparse monotherapy data, and lack of CBC-specific oncology trials materially limit translation. Many in-vitro oncology concentrations may exceed realistic systemic exposure.</td>
</tr>
</table>
<p>TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr</p>